MSH6 and prostate cancer: In the MSH6 non-carrier control cohort, under a scenario of a 100% biopsy compliance rate, the prostate cancer incidence would then be 0·6% (one of 177; 95% CI 0·0–3·1; vs 3·0% [four of 135; 0·8–7·4] in MSH6 carriers), with a difference in incidence of 2·4% (0·7–5·5; p=0·17).